Seewaldt and Buermeyer awarded grand prize from the Global Challenge to Prevent Breast Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Victoria Seewaldt
Nancy Buermeyer
Michele Atlan

The Global Challenge to Prevent Breast Cancer has awarded:

  • The Grand Prize (Researcher Category) to Victoria Seewaldt, professor and chair of Population Sciences at City of Hope, who, with Chris Sistrunk of the SoCAL STEM and Community Outread Team, proposed STEM education to help prevent breast cancer.

  • The Grand Prize (Advocate Category) to Nancy Buermeyer, senior policy strategist at Breast Cancer Prevention Partners, who, with co-author Janet Nudelman, advocates reducing emissions at major ports to lower breast cancer risk.

  • In addition to the two Grand Prize winners chosen by a judging committee of experts and advocates, those in attendance and watching online also had their say, voting on an Audience Choice Award. The winner, Michele Atlan, vice president at the Breast Cancer Care and Research Fund, proposed a novel way to repackage natural ingredients to aid prevention efforts.

Started by the California Breast Cancer Research Program last fall, the Global Challenge was designed to uncover transformative prevention research ideas, and address the staggering statistic that, despite treatment advancements, people continue to be diagnosed with breast cancer at rates that have remained essentially unchanged over the past three decades.

Finalists were selected from dozens of applications that were submitted to the Global Challenge and competed at the Idea Showcase and Competition in San Francisco.

The ideas presented at the Global Challenge Idea Showcase and Competition will inform more than $15 million in funding that CBCRP will devote to breast cancer prevention research over the next five years.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login